Exciting news on the horizon for those exploring weight management solutions! The FDA recently approved Zepbound, also known as Mounjaro, a groundbreaking medication for weight loss. Officially approved as an anti-obesity medication on November 6, this highly anticipated anti-obesity medication is expected to hit pharmacies in the coming months. Sound Medical Weight Loss is already well-acquainted with this class of medications, having incorporated it into their treatment options for the past several years. As we eagerly await its arrival, individuals are encouraged to check with their insurance carriers to see if Zepbound is included in their formulary for weight loss. Its arrival is opening up new possibilities for those navigating the challenges of the conditions of obesity and overweight.
In the realm of scientific advancements, the efficacy of Zepbound in weight loss has been supported by the Tirzepatide study, which revealed a stunning 20-22% body mass reduction. “In the SURMOUNT-1 trial, patients with obesity or overweight (but not diabetes) who received tirzepatide 15 mg, with monthly brief lifestyle counseling, lost 20.9% of baseline weight at 72 weeks (versus 3.1% for placebo) with accompanying reductions in cardiometabolic risk factors.” This research provides valuable insights into the medication's effectiveness, showcasing its dual-action capabilities. As a new player in the field of weight management, Zepbound adds to the arsenal of treatments available for addressing these medical conditions. Stay tuned for more updates on this promising development that could potentially reshape the landscape of weight loss solutions in the near future. Call Sound Medical Weight Loss now to see if Zepbound is a treatment option for you!
Dr. James, ND
Want to read more about the study - Find it here: https://www.nature.com/articles/s41591-023-02597-w
